Loading...
CLBX logo

CelLBxHealth plcAIM:CLBX Stock Report

Market Cap UK£7.7m
Share Price
UK£0.024
My Fair Value
n/a
1Y-70.0%
7D-9.4%
Portfolio Value
​
View

CelLBxHealth plc

AIM:CLBX Stock Report

Market Cap: UK£7.7m

CelLBxHealth (CLBX) Stock Overview

A medical diagnostic company, develops cancer diagnostics products in the United Kingdom, Europe, North America, and internationally. More details

CLBX fundamental analysis
Snowflake Score
Valuation2/6
Future Growth2/6
Past Performance0/6
Financial Health4/6
Dividends0/6

Rewards

Revenue is forecast to grow 90.43% per year

Risk Analysis

Has less than 1 year of cash runway

Highly volatile share price over the past 3 months compared to the UK market

Currently unprofitable and not forecast to become profitable over the next 3 years

Does not have meaningful revenue (£3M)

+ 1 more risk

CLBX Community Fair Values

Create Narrative

See what others think this stock is worth. Follow their fair value or set your own to get alerts.

CLBX logo
CelLBxHealth

Global Aging And Liquid Biopsy Will Redefine Early Cancer Detection

Key Takeaways Rapid scaling of major partnerships and NHS integration could significantly boost contract conversion, recurring revenue, and visibility beyond current expectations. Unique technology positions ANGLE for industry leadership, with direct patient testing and clinical lab accreditation driving premium pricing, market share, and high-margin service expansion.
View narrative
UK£0.3
FV
92.0% undervalued intrinsic discount
238.28%
Revenue growth p.a.
0users have liked this narrative
0users have commented on this narrative
1users have followed this narrative
CLBX logo
CelLBxHealth

Regulatory Scrutiny And Binary Deals Will Hinder Precision Medicine

Key Takeaways Regulatory hurdles and deal timing uncertainty create risks for revenue growth and may lead to irregular or delayed earnings progression despite industry momentum. Heavy reliance on core technology and tight research funding environment expose the company to innovation risk and constrain diversification and profitability improvements.
View narrative
UK£0.17
FV
85.9% undervalued intrinsic discount
52.76%
Revenue growth p.a.
0users have liked this narrative
0users have commented on this narrative
0users have followed this narrative
CLBX logo
CelLBxHealth

Leadership Appointment And Diagnostic Partnerships Will Shape Future Market Expansion

Key Takeaways ANGLE's unique technologies and partnerships in precision oncology position it for strong, margin-expanding revenue growth as liquid biopsy adoption accelerates. Ongoing innovation, clinical validation, and disciplined cost management enhance ANGLE's competitive strength, diversify revenues, and improve long-term profitability.
View narrative
UK£0.1
FV
77.1% undervalued intrinsic discount
221.75%
Revenue growth p.a.
1users have liked this narrative
0users have commented on this narrative
3users have followed this narrative
View Stock Community

CelLBxHealth plc Competitors

Price History & Performance

Summary of share price highs, lows and changes for CelLBxHealth
Historical stock prices
Current Share PriceUK£0.024
52 Week HighUK£0.17
52 Week LowUK£0.015
Beta0.083
1 Month Change-12.73%
3 Month Change-58.26%
1 Year Change-70.00%
3 Year Change-95.38%
5 Year Change-94.76%
Change since IPO-98.39%

Recent News & Updates

Recent updates

User avatar

Pharma Partnerships And Liquid Biopsy Will Expand Future Markets

ANGLE's unique technologies and partnerships in precision oncology position it for strong, margin-expanding revenue growth as liquid biopsy adoption accelerates.

Is ANGLE (LON:AGL) In A Good Position To Invest In Growth?

May 30
Is ANGLE (LON:AGL) In A Good Position To Invest In Growth?

Here's Why We're Watching ANGLE's (LON:AGL) Cash Burn Situation

Jan 22
Here's Why We're Watching ANGLE's (LON:AGL) Cash Burn Situation

Will ANGLE (LON:AGL) Spend Its Cash Wisely?

Sep 27
Will ANGLE (LON:AGL) Spend Its Cash Wisely?

We're Keeping An Eye On ANGLE's (LON:AGL) Cash Burn Rate

Mar 20
We're Keeping An Eye On ANGLE's (LON:AGL) Cash Burn Rate

Will ANGLE (LON:AGL) Spend Its Cash Wisely?

Dec 02
Will ANGLE (LON:AGL) Spend Its Cash Wisely?

We Think ANGLE (LON:AGL) Needs To Drive Business Growth Carefully

Aug 11
We Think ANGLE (LON:AGL) Needs To Drive Business Growth Carefully

We Think ANGLE (LON:AGL) Needs To Drive Business Growth Carefully

Feb 28
We Think ANGLE (LON:AGL) Needs To Drive Business Growth Carefully

ANGLE (LON:AGL) Is In A Good Position To Deliver On Growth Plans

Jul 16
ANGLE (LON:AGL) Is In A Good Position To Deliver On Growth Plans

ANGLE (LON:AGL) Is In A Good Position To Deliver On Growth Plans

Aug 23
ANGLE (LON:AGL) Is In A Good Position To Deliver On Growth Plans

We're Not Very Worried About ANGLE's (LON:AGL) Cash Burn Rate

May 02
We're Not Very Worried About ANGLE's (LON:AGL) Cash Burn Rate

What Type Of Shareholders Make Up ANGLE plc's (LON:AGL) Share Registry?

Feb 14
What Type Of Shareholders Make Up ANGLE plc's (LON:AGL) Share Registry?

We're Keeping An Eye On ANGLE's (LON:AGL) Cash Burn Rate

Dec 22
We're Keeping An Eye On ANGLE's (LON:AGL) Cash Burn Rate

Shareholder Returns

CLBXGB Medical EquipmentGB Market
7D-9.4%1.1%0.5%
1Y-70.0%29.7%17.5%

Return vs Industry: CLBX underperformed the UK Medical Equipment industry which returned 29.7% over the past year.

Return vs Market: CLBX underperformed the UK Market which returned 17.5% over the past year.

Price Volatility

Is CLBX's price volatile compared to industry and market?
CLBX volatility
CLBX Average Weekly Movement27.2%
Medical Equipment Industry Average Movement5.4%
Market Average Movement4.7%
10% most volatile stocks in GB Market10.8%
10% least volatile stocks in GB Market2.6%

Stable Share Price: CLBX's share price has been volatile over the past 3 months compared to the UK market.

Volatility Over Time: CLBX's weekly volatility has increased from 17% to 27% over the past year.

About the Company

FoundedEmployeesCEOWebsite
1994119Peter Collinscellbxhealth.com

CelLBxHealth plc, a medical diagnostic company, develops cancer diagnostics products in the United Kingdom, Europe, North America, and internationally. The company develops Parsortix PC1 systems, a medical device for the capture and harvest of intact circulating tumour cells (CTCs) from metastatic breast cancer patient blood for subsequent user-validated downstream analysis; and Parsortix PR1 system captures and harvests circulating tumour cells from blood. It also provides Portrait+ CTC Staining kit, a ready-to-use laboratory kit with analytical sensitivity and specificity for the identification, characterization, and enumeration of epithelial and mesenchymal circulating tumour cells; and CellKeep Slide, a CTC harvesting technology.

CelLBxHealth plc Fundamentals Summary

How do CelLBxHealth's earnings and revenue compare to its market cap?
CLBX fundamental statistics
Market capUK£7.72m
Earnings (TTM)-UK£15.78m
Revenue (TTM)UK£2.62m
2.9x
P/S Ratio
-0.5x
P/E Ratio

Is CLBX overvalued?

See Fair Value and valuation analysis

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
CLBX income statement (TTM)
RevenueUK£2.62m
Cost of RevenueUK£1.80m
Gross ProfitUK£823.00k
Other ExpensesUK£16.60m
Earnings-UK£15.78m

Last Reported Earnings

Jun 30, 2025

Next Earnings Date

n/a

Earnings per share (EPS)-0.049
Gross Margin31.36%
Net Profit Margin-601.37%
Debt/Equity Ratio0%

How did CLBX perform over the long term?

See historical performance and comparison

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2025/11/03 09:37
End of Day Share Price 2025/10/31 00:00
Earnings2025/06/30
Annual Earnings2024/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

CelLBxHealth plc is covered by 6 analysts. 3 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Samuel EnglandBerenberg
Adam McCarterCavendish
Lucy-Emma Mary Codrington-BartlettEdison Investment Research